Alizé Pharma 3 Raises €67m To Build ‘Fully Fledged’ Biotech
Executive Summary
The Series A financing positions Alizé to take a rival to Shire’s Natpara through to clinical proof of concept over the next few years.
You may also be interested in...
LSP Closes Mega Life Sciences Fund For Europe, But US Still Way Ahead
A new life sciences fund, LSP 6, is one of the largest fundraisings in Europe in the sector, and will invest in around 15-to-18 pharma or medtech companies.
Finance Watch: Cell And Gene Therapy Fundraising Down Overall In Q2, But VC Deals Still Soared
Private Company Edition: ARM's Q2 report shows a 38% decline in financings, but venture capital and upfront fees from deals were robust. Also, Servier raises $405m in the US, Frequency closes a $62m series C and VenatoRx accesses US government cash.
Millendo Gets European Foothold With Alizé Acquisition
The US company is getting hold of livoletide, the French firm's late-stage ready compound for reducing hyperphagia, or insatiable hunger, in patients suffering from the rare genetic disease Prader-Willi Syndrome.